Article Text

Download PDFPDF

Domiciliary long-term non-invasive ventilation in COPD: should we select subgroups with a better likelihood to respond to NIV in subsequent randomised controlled trials?
  1. Jean-Christian Borel1,2,
  2. Christophe Pison3,4,5,
  3. Jean-François Timsit6,7,
  4. Jean-Louis Pepin1,8
  1. 1Univ Grenoble Alpes, HP2 INSERM U1042, Grenoble, France
  2. 2AGIR à dom, Non Profit Home Care Provider, Meylan, France
  3. 3Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, Grenoble University Hospital, Grenoble, France
  4. 4European Institute for Systems Biology and Medicine, EISBM, Lyon, France
  5. 5INSERM 1055, Univ Grenoble Alpes, Grenoble, France
  6. 6Service de Réanimation Médicale, Pôle Urgences Médecine Aigüe, Grenoble University Hospital, Grenoble, France
  7. 7Service de Réanimation Médicale, Hôpital Bichat-APHP, Paris, France
  8. 8Clinique Universitaire de Physiologie et Sommeil, Pôle Thorax et Vaisseaux, Grenoble University Hospital, Grenoble, France
  1. Correspondence to Dr Jean-Christian Borel, AGIR à dom Association, 19, bd de la Chantourne, 38700 La Tronche-France; j.borel{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The efficacy of non-invasive ventilation (NIV) for severe COPD exacerbation has been unambiguously demonstrated. The study by Struik et al recently published in Thorax1 demonstrates that pursuing nocturnal NIV after acute respiratory failure in patients with COPD exhibiting prolonged hypercapnia >48 h after termination of ventilatory support does not reduce time to readmission or rate of deaths at 1 year. They included a mixed cohort of patients with acute-on-chronic and acute respiratory failures. However, in future studies it may be interesting to select patients with persistent hypercapnia several weeks after the acute exacerbation episode. Nevertheless, long-term NIV efficacy for stable COPD remains uncertain in terms of hard outcomes. Clinical cohort studies suggest that mortality and readmission rates under NIV are dependent upon the underlying COPD subgroup.2 ,3

We recently showed that a reduction in risk of death and hospital readmission is obtained only in obese patients with COPD with NIV usage >5 h/day.2 In the Struik study,1 randomisation was stratified on body mass index although the mean body mass index of the whole cohort was 25 kgm−2 (SD around 6 kgm−2). The majority of Struik's cohort had ‘respiratory COPD’ characterised by severe airflow limitation without obesity,4 a subgroup supposed to be less responsive to NIV.2

Obesity is a main risk factor of sleep apnoea, and patients with overlap syndrome (COPD+sleep apnoea) benefit from positive pressure treatment.5 We obtained positive results with NIV in obese patients with COPD after adjustment for all independent risk factors associated with prognosis, particularly sleep apnoea. This suggests that NIV, beyond correcting sleep apnoea, may also lessen the deleterious impact of nocturnal hypoventilation and improve respiratory mechanics.

In Struik's study,1 in both intention to treat and per protocol analyses (threshold for NIV compliance ≥5 h/night) NIV was not effective on time to readmission or death. In our work, we analysed the impact of daily use of NIV as a time-dependent variable without any pre-existing arbitrary threshold. We found a U-shaped curve between NIV usage and risk of readmission or death. This suggests that NIV adherence should be assessed as a continuous variable rather than with a predefined threshold.

In summary, we suggest that subsequent randomised controlled trials be conducted on specific COPD subgroups that have better likelihood of responding to NIV (ie, obese patients with comorbidities and moderate to severe airflow obstruction). This might represent a new approach to the challenging area of long-term NIV in stable patients with COPD.


The authors thank Dr Alison Foote for English editing.


View Abstract


  • Contributors J-LP received personal fees from RESMED and grants from RESMED, PHILIPS and AGIRadom. These fees and grants are outside the submitted work. CP has received grants from AGIRadom, a non-profit home care company. These grants are outside the submitted work.

  • Competing interests J-CB is employed by AGIRadom, a non-profit home care company.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles